Sylvain Fanier

President, Atonco

ATO-101™: A THERAPEUTIC ADVANCE FOR THE TREATMENT OF NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)

ABSTRACT

Non-muscle-invasive bladder cancer (NMIBC) presents a significant medical challenge, with a growing need for novel therapeutic options. Atonco develops a promising approach in the area of alpha-immunotherapy treatment using its first radiopharmaceutical, ATO-101 ([211At]At-girentuximab), a CA-IX antigen radiolabeled with astatine-211. The goal of Atonco’s is to assess the potential of ATO-101™ in treating patients who do not respond to conventional bladder cancer treatments.

Atonco’s preclinical and clinical study results have been published in the Cancers (MDPI) journal in March 2025, highlighting the promising potential of its ATO-101™ in the using astatine-211 of non-muscle-invasive bladder cancer (NMIBC) refractory to standard therapies, including BCG.

SPEAKER BIO

Entrepreneur with a demonstrated history in the management of innovation in the medical industry. Business development professional from concept to market. Graduated Msc. from University Paul Sabatier Toulouse, eMBA from ESSEC Business School Paris.

Return to conference agenda